HOXA11-AS

Summary

HOXA11-AS (HOXA11 antisense RNA, HGNC:24957) is a long non-coding RNA gene on chromosome 7p15.2.

This gene produces a long non-coding RNA in antisense to transcription of the homeobox A11 gene. This transcript may associate with chromatin factors such as Polycomb repressive complex and act as a sponge for microRNAs, thereby participating in the regulation of expression of target genes. High levels of this transcript may be associated with tumor progression.

Source: NCBI Gene 221883 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24957
Approved symbol	HOXA11-AS
Name	HOXA11 antisense RNA
Location	7p15.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	HOXA11-AS1, HOXA11S, HOXA-AS5, NCRNA00076, LncHOXA11
Ensembl gene	ENSG00000240990
Ensembl biotype	lncRNA
OMIM	607530
Entrez	221883
RNAcentral	URS00007333DC — lncRNA, 1628 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 lncRNA

ENST00000479766, ENST00000520360, ENST00000520395, ENST00000522674, ENST00000522863, ENST00000647680, ENST00000647851, ENST00000648491, ENST00000648499, ENST00000650141

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000479766 — 2 exons

Exon	Start	End
ENSE00002057864	27187819	27188020
ENSE00002065189	27188601	27189222

Expression profiles

Bgee: expression breadth ubiquitous, 107 present calls, max score 94.24.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3618 / max 77.2253, expressed in 467 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77815	0.6002	291
77814	0.4722	272
77813	0.2836	131
77812	0.0058	3

Top tissues by expression

107 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	94.24	gold quality
prostate gland	UBERON:0002367	93.64	gold quality
transverse colon	UBERON:0001157	93.33	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.00	gold quality
endocervix	UBERON:0000458	91.70	gold quality
colon	UBERON:0001155	91.22	gold quality
ectocervix	UBERON:0012249	89.80	gold quality
rectum	UBERON:0001052	89.66	gold quality
body of uterus	UBERON:0009853	89.01	gold quality
uterine cervix	UBERON:0000002	88.74	gold quality
stromal cell of endometrium	CL:0002255	88.30	gold quality
myometrium	UBERON:0001296	88.18	gold quality
smooth muscle tissue	UBERON:0001135	87.14	gold quality
vagina	UBERON:0000996	86.92	gold quality
muscle of leg	UBERON:0001383	82.54	gold quality
gastrocnemius	UBERON:0001388	82.37	gold quality
urinary bladder	UBERON:0001255	82.36	gold quality
endometrium	UBERON:0001295	82.06	gold quality
intestine	UBERON:0000160	81.84	gold quality
skeletal muscle tissue	UBERON:0001134	81.35	gold quality
colonic epithelium	UBERON:0000397	78.09	gold quality
tibial artery	UBERON:0007610	76.39	gold quality
popliteal artery	UBERON:0002250	76.30	gold quality
calcaneal tendon	UBERON:0003701	75.29	gold quality
placenta	UBERON:0001987	74.90	gold quality
sural nerve	UBERON:0015488	74.10	gold quality
subcutaneous adipose tissue	UBERON:0002190	73.65	gold quality
metanephros cortex	UBERON:0010533	72.73	gold quality
tibial nerve	UBERON:0001323	70.86	gold quality
hindlimb stylopod muscle	UBERON:0004252	67.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.80

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• These findings demonstrate for the first time a role for HOXA11-AS in epithelial ovarian cancer with effects that could be modified by germline variants (PMID:26430965)
• a model in which the EZH2/HOXA11-AS/LSD1 complex and HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis. (PMID:27651312)
• These findings highlight the clinical significance of HOXA11as to predicting the prognosis of SOC patients and suggest its potential in promoting tumor aggressiveness via regulation of vascular endothelial growth factor (VEGF), MMP-9, and EMT-related mechanisms. (PMID:27737536)
• HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. (PMID:27792998)
• Findings show that HOXA11-AS not only could promote gastric cancer (GC) cells migration and invasion in vitro, but also promotes GC cells metastasis in vivo, at least in part, by regulating beta-catenin and KLF2. (PMID:28441948)
• HOXA11-AS plays a significant role in non-small cell lung cancer proliferation, invasion, migration, apoptosis and cell cycle. (PMID:28717185)
• our data suggested that the transcript level of HOXA11AS was highly upregulated in breast cancer both in vivo and in vitro. Knockdown of HOXA11AS in MDAMB231 and MDAMB436 cells inhibited colony formation and cell proliferative rate, and caused cell cycle arrest in G0/G1 phase. (PMID:28791375)
• increased expression of HOXA11-AS is a risk factor for poor clinical outcomes in numerous tumors (PMID:28942241)
• HOXA11-AS acted as an oncogenic long non-coding RNA that promoted cell growth and metastasis of glioma through regulating miR-214-3p/EZH2 axis. (PMID:28946213)
• study findings suggest that homeobox (HOX)A11-AS1 (HOXA11-AS1) lncRNA may play a role in the development of peritoneal endometriosis, but HOXA11-AS1 may not influence endometrial receptivity in endometriosis-associated infertility. (PMID:29017417)
• HOXA11-AS suppressed cell proliferation and promoted cell apoptosis via targeting mir-124-3p and knockdown inhibited cell apoptosis. (PMID:29164588)
• HOXA11-AS could promote renal cancer cells growth and invasion by modulating miR-146b-5p-MMP16 axis. (PMID:29953617)
• Glioma patients with high LncRNA HOXA11-AS expression had shorter overall survival time than those with low expression. Silencing HOXA11-AS significantly increased miR-124-3p expression. (PMID:30064227)
• lncRNA HOXA11-AS acted as a ceRNA to promote cisplatin resistance of human LUAD cells via the miR-454-3p/Stat3 axis. (PMID:30099826)
• lncRNA HOXA11-AS was overexpressed in glioma and overexpression was correlated with advanced stages of glioma and poor prognosis. Downregulating HOXA11-AS expression significantly suppressed proliferation, migration and invasion of glioma cells and increased their apoptosis. HOXA11-AS exerted its oncogenic effects by binding to miR-130a-5p, thereby neutralizing the suppressive effect of miR-130a-5p on HMGB2. (PMID:30657566)
• Propofol promotes apoptosis of colorectal cancer cells via alleviating the suppression of lncRNA HOXA11-AS on miRNA let-7i. (PMID:31013434)
• HOXA11-AS regulates JAK-STAT pathway by miR-15a-3p/STAT3 axis to promote the growth and metastasis in liver cancer. (PMID:31099097)
• Data found that HOXA11-AS was upregulated in cisplatin resistant lung adenocarcinoma tumors and cell lines. Functional analysis showed that the knockdown of HOXA11-AS expression in A549 cells inhibits cell proliferation, induces G1 phase cell cycle arrest and apoptosis. (PMID:31144606)
• Up-regulation of HOXA11-AS was found in gastric cancer (GC) tissues, cell lines, and serum samples. Decreased serum HOXA11-AS levels were negatively related with tumor size, TNM stage, and lymph node metastasis and were associated with a better overall survival rate. HOXA11-AS promoted GC cell proliferation and invasion. SRSF1 may be the target regulated by HOXA11-AS in GC cells. (PMID:31235999)
• The findings highlight the importance of HOXA11-AS/miR-214-3p/PIM1 axis in the drug resistance of oral squamous cell carcinoma. (PMID:31275988)
• LncRNA HOXA11-AS regulates calcium oxalate crystal-induced renal inflammation via miR-124-3p/MCP-1. (PMID:31680444)
• LncRNA HOXA11-AS promotes OSCC progression by sponging miR-98-5p to upregulate YBX2 expression. (PMID:31731187)
• Long non-coding RNA HOXA11-AS accelerates the progression of keloid formation via miR-124-3p/TGFbetaR1 axis. (PMID:31878829)
• CTCF was validated to activate HOXA11-AS transcription in PCa cells. (PMID:31971633)
• LncRNA HOXA11-AS promotes migration and invasion through modulating miR-148a/WNT1/beta-catenin pathway in gastric cancer. (PMID:32009419)
• Recent advances in unraveling the molecular mechanisms and functions of HOXA11AS in human cancers and other diseases (Review). (PMID:32236611)
• Long Noncoding RNA HOXA11-AS Modulates the Resistance of Nasopharyngeal Carcinoma Cells to Cisplatin via miR-454-3p/c-Met. (PMID:33115978)
• LncRNA HOXA11-AS Aggravates Keloid Progression by the Regulation of HOXA11-AS-miR-205-5p-FOXM1 Pathway. (PMID:33261854)
• Long Noncoding RNA HOXA11-AS and Transcription Factor HOXB13 Modulate the Expression of Bone Metastasis-Related Genes in Prostate Cancer. (PMID:33514011)
• Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson’s disease model via targeting miR-124-3p mediated FSTL1/NF-kappaB axis. (PMID:33839699)
• Long noncoding HOXA11-AS knockdown suppresses the progression of non-small cell lung cancer by regulating miR-3619-5p/SALL4 axis. (PMID:34050851)
• LncRNA HOXA11-AS promotes cell growth by sponging miR-24-3p to regulate JPT1 in prostate cancer. (PMID:34337714)
• LncRNA HOXA11-AS aggravates the keloid formation by targeting miR-148b-3p/IGFBP5 axis. (PMID:34655977)
• Increased expression of HOXA11-AS attenuates endometrial decidualization in recurrent implantation failure patients. (PMID:35114391)
• Uterine HOXA11 antisense long non-coding RNA prevents decidualization: A new pathway-regulating pregnancy. (PMID:35320748)
• The minor allele of rs17427875 in long non-coding RNA-HOXA11-AS influences the prognosis of subarachnoid hemorrhage (SAH) via modulating miR-15a and STAT3 expression. (PMID:35700456)
• Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer. (PMID:35706412)
• The long noncoding RNA HOXA11-AS promotes lung adenocarcinoma proliferation and glycolysis via the microRNA-148b-3p/PKM2 axis. (PMID:35924724)
• An Axis between the Long Non-Coding RNA HOXA11-AS and NQOs Enhances Metastatic Ability in Oral Squamous Cell Carcinoma. (PMID:36142607)
• LncRNA HOXA11-AS modulates the miR-148b-3p/MLPH axis to promote prostate cancer cell proliferation. (PMID:37300684)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.